REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2017

Primary Completion Date

December 1, 2018

Study Completion Date

December 31, 2019

Conditions
Renal Cell CarcinomaKidney Cancer
Interventions
DRUG

Iodine (124I) Girentuximab

i.v.

Trial Locations (8)

10021

Memorial Sloan-Kettering Cancer Center, New York

27711

Duke University Medical Center, Durham

33612

H. Lee Moffitt Cancer Center & Research Center, Tampa

43210

Ohio State University, Columbus

90095-1721

David Geffen School of Medicine, UCLA, Los Angeles

01805

Lahey Clinic, Burlington

19104-4283

Fox Chase Cancer Center, Philadelphia

77030-4009

MD Anderson, Houston

Sponsors
All Listed Sponsors
lead

Heidelberg Pharma AG

INDUSTRY